These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30454971)

  • 1. Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast.
    Van Bockstal M; Lambein K; Smeets A; Slembrouck L; Neven P; Nevelsteen I; Weltens C; Van Limbergen E; Christiaens MR; Van Ongeval C; Wildiers H; Libbrecht L; Floris G
    Eur J Surg Oncol; 2019 Apr; 45(4):550-559. PubMed ID: 30454971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast.
    Van Bockstal M; Lambein K; Gevaert O; De Wever O; Praet M; Cocquyt V; Van den Broecke R; Braems G; Denys H; Libbrecht L
    Histopathology; 2013 Oct; 63(4):520-33. PubMed ID: 23889174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipsilateral local recurrence in relation to therapy and morphological characteristics in patients with ductal carcinoma in situ of the breast.
    Ringberg A; Idvall I; Fernö M; Anderson H; Anagnostaki L; Boiesen P; Bondesson L; Holm E; Johansson S; Lindholm K; Ljungberg O; Ostberg G
    Eur J Surg Oncol; 2000 Aug; 26(5):444-51. PubMed ID: 11016463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphological intratumor heterogeneity in ductal carcinoma in situ of the breast.
    Stanciu-Pop C; Nollevaux MC; Berlière M; Duhoux FP; Fellah L; Galant C; Van Bockstal MR
    Virchows Arch; 2021 Jul; 479(1):33-43. PubMed ID: 33502600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS score™ result.
    Alvarado M; Carter DL; Guenther JM; Hagans J; Lei RY; Leonard CE; Manders J; Sing AP; Broder MS; Cherepanov D; Chang E; Eagan M; Hsiao W; Schultz MJ
    J Surg Oncol; 2015 Jun; 111(8):935-40. PubMed ID: 26031501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of predictive factors, particularly the Van Nuys index, of local recurrence in ductal carcinoma in situ of the breast: study of 166 cases with conservative treatment and review of the literature].
    Denoux Y; Marnay J; Crouet H; Boute V; Delozier T; Vie B; Chasle J
    Bull Cancer; 2001 Apr; 88(4):419-25. PubMed ID: 11371378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local recurrence outcomes after breast conserving surgery and adjuvant radiotherapy in ductal carcinoma in situ of the breast and a comparison with ECOG E5194 study.
    Ozkaya Akagunduz O; Ergen A; Erpolat P; Gultekin M; Akkus Yildirim B; Parvizi M; Ikiz D; Colpan Oksuz D; Onal C; Yildiz F; Ozsaran Z
    Breast; 2018 Dec; 42():10-14. PubMed ID: 30121548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery.
    Punglia RS; Jiang W; Lipsitz SR; Hughes ME; Schnitt SJ; Hassett MJ; Nekhlyudov L; Achacoso N; Edge S; Javid SH; Niland JC; Theriault RL; Wong YN; Habel LA
    Breast Cancer Res Treat; 2018 Feb; 167(3):751-759. PubMed ID: 29079937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.
    Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B
    Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
    Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
    Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypofractionation Is an Acceptable Alternative to Conventional Fractionation in the Treatment of Postlumpectomy Ductal Carcinoma In Situ With Radiotherapy.
    Isfahanian N; Al-Hajri T; Marginean H; Chang L; Caudrelier JM
    Clin Breast Cancer; 2017 Apr; 17(2):e77-e85. PubMed ID: 27889437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ductal carcinoma in situ--the influence of the radiotherapy boost on local control.
    Wong P; Lambert C; Agnihotram RV; David M; Duclos M; Freeman CR
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e153-8. PubMed ID: 21664063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.
    Van Bockstal MR; Agahozo MC; Koppert LB; van Deurzen CHM
    Int J Cancer; 2020 Mar; 146(5):1189-1197. PubMed ID: 31018242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the van nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examined by serial macroscopic sectioning: practical considerations.
    de Mascarel I; Bonichon F; MacGrogan G; de Lara CT; Avril A; Picot V; Durand M; Mauriac L; Trojani M; Coindre JM
    Breast Cancer Res Treat; 2000 May; 61(2):151-9. PubMed ID: 10942101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective use of whole breast radiotherapy after breast conserving surgery for invasive breast cancer and DCIS.
    Skandarajah AR; Bruce Mann G
    Surgeon; 2013 Oct; 11(5):278-85. PubMed ID: 23632044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
    Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast.
    Macdonald HR; Silverstein MJ; Lee LA; Ye W; Sanghavi P; Holmes DR; Silberman H; Lagios M
    Am J Surg; 2006 Oct; 192(4):420-2. PubMed ID: 16978941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of postoperative radiotherapy in reducing ipsilateral recurrence in DCIS: an observational study of 1048 cases.
    Corradini S; Pazos M; Schönecker S; Reitz D; Niyazi M; Ganswindt U; Schrodi S; Braun M; Pölcher M; Mahner S; Harbeck N; Engel J; Belka C
    Radiat Oncol; 2018 Feb; 13(1):25. PubMed ID: 29426355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation Therapy Following Breast Conserving Surgery for Ductal Carcinoma in situ: Yes or No?
    Stoleru LS; Stoleru S
    Chirurgia (Bucur); 2017; 112(4):403-412. PubMed ID: 28862116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.